Log in to your Inderes Free account to see all free content on this page.

OncoZenge

6.40 SEK

+2.56%

Less than 1K followers

ONCOZ

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Quarter data

Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for OncoZenge

Q4/242024Q1/25Q2/25Q3/25Q4/252025Q1/26
Revenue2.72.7
EBITDA-2.5-8.70.0-2.6-3.5
EBIT-2.5-8.70.0-2.6-3.5-9.7-15.8-6.8
EBIT-%1.5 %-592.6 %
Profit before taxes-2.5-8.70.0-2.6-3.5-9.9-15.9-7.1
Net income-2.5-8.70.0-2.6-3.5-9.9-15.9-7.1
Login required

This content is only available for logged in users